Acetorphan is an orally active inhibitor of enkephalinase (EC 3.4.24.11) with antidiarrhoeal activity in rodents apparently through protection of endogenous enkephalins and a purely antisecretory mechanism. Its antidiarrhoeal activity in man was assessed in an experimental model of cathartic induced secretory diarrhoea as well as in acute diarrhoea. of presumed infectious origin. In six healthy volunteers receiving castor oil and pretreated with acetorphan or placebo in a crossover controlled trial, the drug significantly decreased the number and weight of stools passed during 24 hours. About 200 outpatients with severe acute diarrhoea (more than five stools per day) were included in a randomised double blind study of acetorphan against placebo. The significant antidiarrhoeal activity of acetorphan was established using a variety of criteria: (i) the duration of both diarrhoea and treatment were diminished; (ii) no acetorphan treated patient withdrew from the study whereas five dropped out because of worsening in the placebo group; (iii) the frequency of symptoms associated with diarrhoea -for example, abdominal pain or distension, nausea and anorexia -remaining after two weeks was nearly halved; (iv) using visual analogue scales acetorphan treatment was found more effective than placebo by both investigators and patients. There was statistically no significant difference between acetorphan and placebo in respect of side effects, particularly constipation, which often accompanies the antidiarrhoeal activity of mu opioid receptor agonists this difference is attributable to the lack of antipropulsive activity of acetorphan in man. The efficacy and tolerance of acetorphan suggest that enkephalinase inhibition may represent a novel therapeutic approach for the symptomatic management of acute secretory diarrhoea without impairing intestinal transit.
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It is generally admitted that acute infectious diarrhoea is accompanied with an abnormality of intestinal water and electrolyte transport. ' As a consequence rehydration with Patients were given two capsules at the start of the study and were instructed to take one capsule after each unformed bowel movement. Drug administration was continued until recovery, defined as the disappearance of any unformed stool, or for a maximum of 10 days. The remaining capsules were returned to the investigators and were counted to determine the actual number of capsules ingested. No other new treatment was allowed during the trial, except for paracetamol.
STUDY DESIGN
The patients were seen twice by clinicians not informed of the nature of treatments: for the first time at inclusion (visit 1) and 10-14 days later (visit 2). For each patient the clinicians had a case report form to complete at visits 1 and 2. It included a specific questionnaire with a report of clinical examinations. The clinicians remained blind all over the study.
Patients were requested to keep a diary in which the following information was reported: time, number and characters of bowel movements, number of capsules taken, possible adverse affects, and their global evaluation of the treatment using visual analogic scales (from 0= no efficacy, to 100=excellent efficacy). Patients were asked to bring back the diary and remaining capsules at visit 2 and both were checked by the clinicians.
The duration of diarrhoea was defined as the time from the first dose of the trial drug (visit 1) to resolution of diarrhoea, that is the disappearance of unformed stools.
The tolerance was assessed using the spontaneously described symptoms and the visual analogue scales (from 0 to 100-that is, from bad to excellent tolerance). For the next 24 hours, the first one occurring after 4-8 (1 1) hours and the total stool weight being 672 (76) g (Table I and Fig 1) . Among the six subjects, two had taken acetorphan during the first session and four during the second session of the trial. The effect of the treatment on total stool weights was independent of the order of treatment (p=0188) and there was no interaction between order and treatment (p=0 540). There was a significant reduction (-37%) of stool weight under the action of acetorphan (p=0.009), all six subjects considered individually having a lower stool weight during the acetorphan session than during the placebo session (Fig 2) . In addition the mean number of stools during the trial was reduced by 50% (p<0-002) during the acetorphan session as compared with the placebo session. There was also a tendency toward an extended delay (+ 113%) between administration ofthe cathartic and passage of the first stool but the difference failed to reach significance (Table I) .
All subjects reported a feeling of nausea and discomfort during the two sessions which can, therefore, be attributed to the intake of castor oil but no other side effect was reported. patients, 96 received acetorphan and 98 placebo. There were no significant differences in the various characteristics of the groups on admission (Table II) 42 52 Weight(kg)* 65-1(1-1) 65.8(1-2)
Duration of diarrhoea before inclusion (days)* 1-7 (0-1) Duration of diarrhoea after admission (days) 0 00 1). Using the actuarial approach -that is, determining the probability of unresolved diarrhoea at each day after admission, all the patients were taken into account and their recovery was faster in the acetorphan group than in the placebo group (p<O0OOl) (Fig 3) . For instance on day 4, the cumulative probabilities of recovery were 75 (5)% and 37 (5) The duration of treatment and the total number of capsules taken were significantly less in the acetorphan group than in the placebo group (Table IV) .
The evaluations of global therapeutic efficacy by the physicians and the patients, using visual analogue scales, were in good agreement and showed, in both cases, a highly significant superiority of acetorphan over placebo (Table  IV) .
TOLERANCE
The frequency and the nature of the spontaneously reported adverse effects were similar in the two treatment groups, particularly constipation was rare in both groups (Table V) .
Discussion
The antidiarrhoeal activity of acetorphan was established here on an experimental model of diarrhoea as well as on acute diarrhoea of presumed infectious origin.
The drug action on the castor oil induced diarrhoea was characterised by significant reductions (by about 40-50%) in the number and weight of stools passed during 24 hours; there was also a doubling of the delay for the passage of the first stool but this failed to reach significance (Table I ). All these changes were qualitatively similar to those induced by acetorphan (or loperamide) in castor oil treated rodents. 7 Because, in these animals, there was a complete inhibition of the antidiarrhoeal effect of enkephalinase inhibitors by naloxone, an opiate receptor blocker, it appears likely that the effect of these agents results from protection of endogenous enkephalins. This protection presumably occurs at the level of peripheral tissues because (i) acetorphan given by oral route is readily hydrolysed into the active inhibitor thiorphan21 which does not cross the blood brain barrier9 20; (ii) in rats enkephalinase inhibitors are devoid of antidiarrhoeal activity when administered intracerebroventricularly and, when administered intraperitoneally, their action is not blocked by intracerebroventricular naloxone. 27 The diarrhoea induced by castor oil, which appears to result from changes in fluid and electrolyte transport39`4 and not from stimulation of gastrointestinal smooth muscle contractility,4' 42 seems a valid model of experimental hypersecretory diarrhoea. Accordingly delta %=-nX 100/number of patients who had this svmptom or sign on visit 1. Comparison between acetorphan and placebo groups using a two tailed Student's t test. *p<0.05; tp<0-01; tp<0 001; NS: not significant. p<O-01; tp<0-001. (2) 87 (2) Values are means (SEM). There was no significant difference between treatment groups. opioid receptor agonists and enkephalinase inhibitors, both devoid of antimotility effects, were recently found active on this model. In fact a similar mechanism may mediate the final action of both classes of compounds as delta receptor agonists exert antisecretory effects triggered either directly on the intestinal mucosa or indirectly via receptors43 of the submucosal plexus.""47 Acetorphan was shown to reduce, in a naloxone reversible manner, the net fluxes of water, Na+ and K+ in the jejunum of cholera toxin treated dogs4849 as well as to block inflammatory fluid secretion in the cat gall bladder. 50 The second trial established the activity of acetorphan in acute diarrhoea, as judged from a large variety of criteria. For instance, all five patients who spontaneously withdrew from the study before completion had received placebo. At the end of the trial -that is, after [13] [14] days, a significantly higher proportion of patients receiving placebo still had diarrhoea than when treated with acetorphan (23% against 7%, p<O002); the duration of treatment and total number of capsules taken were significantly lower in the acetorphan group; the duration of diarrhoea was significantly reduced after acetorphan as judged for instance by the probability of recovery on day 4 (75% against 37%, p<O0OOl); at the end of study the frequency of clinical signs traditionally associated with diarrhoea either spontaneously reported by the patient -for example, sensation of anal burning, nausea, anorexia -or recorded by the investigator -for example, pain on abdominal palpation or abdominal distension -was about two-fold higher in the placebo group; finally both the investigators and patients found the acetorphan treatment significantly (p<OOOl) more effective than treatment with placebo.
Although all these criteria unambiguously establish the antidiarrhoeal efficacy of a new therapeutic class, the possible benefit expected from its use has to be carefully weighed: acute diarrhoea is considered, in most cases, as a self limiting disease and the use of drugs such as mu opiate receptor agonists is often regarded as unnecessary and potentially unsafe. Nevertheless, it should be underlined that, in a population of rather severely affected patients, like the one studied here (as shown by the mean number of stools at inclusion -that is, more than five per day), about 25% ofthe subjects receiving placebo had still diarrhoea and associated symptoms about two weeks after the start of the disease. The discomfort of patients and social cost associated with such a persistence of the disease state should be taken into account.
As far as side effects are concerned, enkephalinase inhibitors appear to be devoid of the major ones associated with the use of antidiarrhoeal mu opiate receptor agonists. Even when crossing the 'blood-brain barrier' (which is not the case for acetorphan given orally), these compounds do not depress the respiratory centres in the central nervous system and are devoid of dependence induction liability.28295' In addition the central nervous system side effects, such as dizziness or irritability, reported with mu receptor agonists, even those purported to enter the brain with difficulty,8 were not detected here. The lack of antimotility effects of acetorphan in rodents2728 and healthy volunteers52 was confirmed in the present trial by the fact that the occurrence of constipation did not significantly differ in the two groups. Constipation is consistently induced by mu receptor agonists.5354 In agreement, in a double blind randomised trial against loperamide in acute diarrhoea, acetorphan was found at least as effective as the mu receptor agonist as an antidiarrhoeal agent but to induce significantly less reactive constipation (Roge, Baumer, Berard, Schwartz and Lecomte, submitted). From these differences, it can be reasonably expected that side effects associated with antimotility drugsfor example, facilitation of bacterial colonisation, invasion by Shigella, extension of the period of excretion of bacterial pathogens and precipitation of ileus and bowel dilatation ('toxic megacolon')9' should not occur with enkephalinase inhibitors. 
